AR053575A1 - Combinacion para la terapia de hiperplasia benigna de prostata - Google Patents
Combinacion para la terapia de hiperplasia benigna de prostataInfo
- Publication number
- AR053575A1 AR053575A1 ARP060101410A ARP060101410A AR053575A1 AR 053575 A1 AR053575 A1 AR 053575A1 AR P060101410 A ARP060101410 A AR P060101410A AR P060101410 A ARP060101410 A AR P060101410A AR 053575 A1 AR053575 A1 AR 053575A1
- Authority
- AR
- Argentina
- Prior art keywords
- controlled release
- release formulation
- combination
- inhibitor
- benign hyperplasia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005016981A DE102005016981A1 (de) | 2005-04-13 | 2005-04-13 | Kombination zur Therapie bei benigner Prostatahyperplasie |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053575A1 true AR053575A1 (es) | 2007-05-09 |
Family
ID=36608700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101410A AR053575A1 (es) | 2005-04-13 | 2006-04-11 | Combinacion para la terapia de hiperplasia benigna de prostata |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1888075A1 (fr) |
JP (1) | JP2008535877A (fr) |
KR (1) | KR20080007252A (fr) |
CN (1) | CN101193638A (fr) |
AR (1) | AR053575A1 (fr) |
AU (1) | AU2006233567A1 (fr) |
BR (1) | BRPI0610634A2 (fr) |
CA (1) | CA2605224A1 (fr) |
CR (1) | CR9427A (fr) |
DE (1) | DE102005016981A1 (fr) |
DO (1) | DOP2006000074A (fr) |
GT (1) | GT200600145A (fr) |
IL (1) | IL186604A0 (fr) |
MA (1) | MA29683B1 (fr) |
MX (1) | MX2007012567A (fr) |
PE (1) | PE20061338A1 (fr) |
RU (1) | RU2007141518A (fr) |
SV (1) | SV2008002477A (fr) |
TN (1) | TNSN07385A1 (fr) |
TW (1) | TW200716122A (fr) |
UY (1) | UY29473A1 (fr) |
WO (1) | WO2006108519A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
CA2633570A1 (fr) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Combinaison pharmaceutique d'un inhibiteur de pde-5 et d'un inhibiteur de 5-alpha reductase |
EP1875914A1 (fr) * | 2006-07-07 | 2008-01-09 | Teva Pharmaceutical Industries Ltd. | Les compositions solides comprenant tadalafil et au moins d'un agent de support |
DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
AU2008334932B2 (en) | 2007-12-13 | 2014-05-22 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
CA2709104C (fr) | 2007-12-13 | 2017-06-13 | Vanda Pharmaceuticals Inc. | Procede et composition pour traiter une affection vehiculee par recepteur de la serotonine |
US8885621B2 (en) | 2010-04-26 | 2014-11-11 | Intel Corporation | Method, apparatus and system for switching traffic streams among multiple bands |
WO2013123965A1 (fr) * | 2012-02-20 | 2013-08-29 | Synthon Bv | Formulation pharmaceutique à dose fixe |
CN102727456B (zh) * | 2012-07-03 | 2016-06-22 | 北京科信必成医药科技发展有限公司 | 药物口腔崩解片及其制备方法 |
AU2014299447B2 (en) * | 2013-06-28 | 2019-01-17 | Hanmi Pharm. Co., Ltd. | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin |
CA2919198A1 (fr) | 2013-07-23 | 2015-01-29 | Allergan, Inc. | Methodes et compositions comprenant de la desmopressine combinee a un agoniste du recepteur adrenergique beta-3 |
KR20150056443A (ko) * | 2013-11-15 | 2015-05-26 | 한미약품 주식회사 | 타다라필 및 암로디핀을 포함하는 복합제제 |
EP3150201B1 (fr) * | 2014-06-30 | 2020-02-19 | Hanmi Pharm. Co., Ltd. | Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite |
WO2016003181A1 (fr) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | Préparation composite comprenant une couche de revêtement par film contenant un principe actif |
WO2016003180A1 (fr) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite |
KR20240010751A (ko) * | 2014-11-20 | 2024-01-24 | 세레니티 파마슈티컬즈 엘엘씨 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
WO2017171508A1 (fr) * | 2016-03-31 | 2017-10-05 | 한미약품 주식회사 | Préparation d'une capsule composite contenant du tadalafil et de la tamsulosine et ayant une stabilité et une vitesse d'élution améliorées |
KR101835506B1 (ko) * | 2016-10-25 | 2018-03-07 | 주식회사 에스텍파마 | 두타스테리드와 타다라필을 함유하는 속효성 복합정제 |
CN108066347B (zh) * | 2016-11-16 | 2021-02-02 | 深圳万和制药有限公司 | 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物 |
KR101879133B1 (ko) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법 |
TR201715231A2 (tr) * | 2017-10-09 | 2019-04-22 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
-
2005
- 2005-04-13 DE DE102005016981A patent/DE102005016981A1/de not_active Withdrawn
-
2006
- 2006-03-29 DO DO2006000074A patent/DOP2006000074A/es unknown
- 2006-03-31 CN CNA2006800207814A patent/CN101193638A/zh active Pending
- 2006-03-31 AU AU2006233567A patent/AU2006233567A1/en not_active Abandoned
- 2006-03-31 WO PCT/EP2006/002941 patent/WO2006108519A1/fr active Application Filing
- 2006-03-31 JP JP2008505765A patent/JP2008535877A/ja active Pending
- 2006-03-31 MX MX2007012567A patent/MX2007012567A/es not_active Application Discontinuation
- 2006-03-31 RU RU2007141518/15A patent/RU2007141518A/ru unknown
- 2006-03-31 BR BRPI0610634-0A patent/BRPI0610634A2/pt not_active Application Discontinuation
- 2006-03-31 KR KR1020077026260A patent/KR20080007252A/ko not_active Application Discontinuation
- 2006-03-31 CA CA002605224A patent/CA2605224A1/fr not_active Abandoned
- 2006-03-31 EP EP06723901A patent/EP1888075A1/fr not_active Withdrawn
- 2006-04-07 SV SV2006002477A patent/SV2008002477A/es not_active Application Discontinuation
- 2006-04-10 GT GT200600145A patent/GT200600145A/es unknown
- 2006-04-11 AR ARP060101410A patent/AR053575A1/es unknown
- 2006-04-11 PE PE2006000383A patent/PE20061338A1/es not_active Application Discontinuation
- 2006-04-12 TW TW095112920A patent/TW200716122A/zh unknown
- 2006-04-12 UY UY29473A patent/UY29473A1/es not_active Application Discontinuation
-
2007
- 2007-10-09 CR CR9427A patent/CR9427A/es not_active Application Discontinuation
- 2007-10-11 IL IL186604A patent/IL186604A0/en unknown
- 2007-10-11 TN TNP2007000385A patent/TNSN07385A1/en unknown
- 2007-10-29 MA MA30335A patent/MA29683B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2006000074A (es) | 2006-10-15 |
CA2605224A1 (fr) | 2006-10-19 |
TW200716122A (en) | 2007-05-01 |
BRPI0610634A2 (pt) | 2010-07-13 |
EP1888075A1 (fr) | 2008-02-20 |
WO2006108519A1 (fr) | 2006-10-19 |
PE20061338A1 (es) | 2007-01-28 |
UY29473A1 (es) | 2006-11-30 |
MA29683B1 (fr) | 2008-08-01 |
AU2006233567A1 (en) | 2006-10-19 |
RU2007141518A (ru) | 2009-05-20 |
GT200600145A (es) | 2007-04-10 |
SV2008002477A (es) | 2008-02-08 |
IL186604A0 (en) | 2008-01-20 |
TNSN07385A1 (en) | 2009-03-17 |
MX2007012567A (es) | 2007-12-10 |
DE102005016981A1 (de) | 2006-10-19 |
JP2008535877A (ja) | 2008-09-04 |
CR9427A (es) | 2007-12-17 |
KR20080007252A (ko) | 2008-01-17 |
CN101193638A (zh) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053575A1 (es) | Combinacion para la terapia de hiperplasia benigna de prostata | |
DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
ECSP109934A (es) | Compuesto - 946 | |
AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
WO2015193740A3 (fr) | Combinaisons thérapeutiques d'un inhibiteur de la tkb, d'un inhibiteur de la pi3k et/ou d'un inhibiteur de la jak-2 | |
CO6612228A2 (es) | Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer | |
CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
CL2008001364A1 (es) | Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos. | |
PE20151070A1 (es) | Inhibidores de la tirosina - quinasa de bruton | |
CR11499A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
NO20071078L (no) | Antivirale forbindelser | |
NO20070866L (no) | Antivirale forbindelser. | |
CL2011000710A1 (es) | Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer. | |
CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
MX2019003134A (es) | Terapia de combinacion. | |
CR20130459A (es) | DERIVADOS DE PIRIDINIL- Y PIRAZINIL-METILOXI-ARIL ÚTILES COMO INHIBIDORES DE TIROSINA CINASA DEL BAZO (Syk) | |
CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. | |
CL2014000606A1 (es) | Combinacion farmaceutica que comprende al compuesto 2-{2-[(2s)-2-metil-2,3-dihidro-1h-indol-1-il]-2-oxoetil}-6-(morfolin-4-il)pirimidin-4-(3h)-ona y al menos un inhibidor de la via de mapk; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento del cancer. | |
PA8578001A1 (es) | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas | |
PE20170469A1 (es) | Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo | |
AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino | |
PE20220250A1 (es) | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma | |
CL2021001830A1 (es) | Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa | |
AR065918A1 (es) | Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzina 5 alfa-reductasa y un antagonista de los receptores 1-adrenergicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |